Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. (2s)-n-((1s)-1-benzyl-2-(((1s)-3-methyl-1-(((2r)-2-methyloxiran-2-yl)carbonyl)butyl)amino)-2-oxoethyl)-4-methyl-2-(((2s)-2-((morpholin-4-ylacetyl)amino)-4-phenylbutanoyl)amino)pentanamide
2. Kyprolis
3. Pr-171
4. Pr171
1. 868540-17-4
2. Kyprolis
3. Carfilzomib (pr-171)
4. Pr-171
5. Carfilzomib (pr171)
6. Unii-72x6e3j5ar
7. Nsc-758252
8. 72x6e3j5ar
9. Chembl451887
10. Chebi:65347
11. Ncgc00249613-01
12. Dsstox_cid_28616
13. Dsstox_rid_82886
14. Dsstox_gsid_48690
15. (2s)-4-methyl-n-[(2s)-1-[[(2s)-4-methyl-1-[(2r)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]-2-[[(2s)-2-[(2-morpholin-4-ylacetyl)amino]-4-phenylbutanoyl]amino]pentanamide
16. (2s)-n-((1s)-1-benzyl-2-(((1s)-3-methyl-1-(((2r)-2-methyloxiran-2-yl)carbonyl)butyl)amino)-2-oxoethyl)-4-methyl-2-(((2s)-2-((morpholin-4-ylacetyl)amino)-4-phenylbutanoyl)amino)pentanamide
17. (alphas)-alpha-[[2-(4-morpholinyl)acetyl]amino]benzenebutanoyl-l-leucyl-n-[(1s)-3-methyl-1-[[(2r)-2-methyl-2-oxiranyl]carbonyl]butyl]-l-phenylalaninamide
18. (s)-4-methyl-n-((s)-1-(((s)-4-methyl-1-((r)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)-2-((s)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide
19. N-{(2s)-2-[(morpholin-4-ylacetyl)amino]-4-phenylbutanoyl}-l-leucyl-n-{(2s)-4-methyl-1-[(2r)-2-methyloxiran-2-yl]-1-oxopentan-2-yl}-l-phenylalaninamide
20. (s)-4-methyl-n-((s)-1-((s)-4-methyl-1-((r)-2-methyloxiran-2-yl)-1-oxopentan-2-ylamino)-1-oxo-3-phenylpropan-2-yl)-2-((s)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide
21. Carfilzomib [usan]
22. Cas-868540-17-4
23. Carfilzomib [usan:inn]
24. Mfcd11040997
25. Kyprolis (tn)
26. Carfilzomib; Pr171
27. Carfilzomib [mi]
28. Carfilzomib [inn]
29. Carfilzomib [jan]
30. Carfilzomib [vandf]
31. Schembl85165
32. Carfilzomib [who-dd]
33. Mls006011102
34. Carfilzomib (jan/usan/inn)
35. Gtpl7420
36. Dtxsid4048690
37. Amy4357
38. Carfilzomib [orange Book]
39. Ex-a2037
40. Ono-7057
41. Tox21_113079
42. Bdbm50277889
43. Nsc756640
44. Nsc758252
45. S2853
46. Zinc49841054
47. Akos025401910
48. Tox21_113079_1
49. Ccg-270405
50. Cs-0984
51. Cs-w004540
52. Db08889
53. Nsc 758252
54. Nsc-756640
55. Ncgc00249613-02
56. Ncgc00249613-03
57. Ncgc00249613-08
58. Ncgc00249613-11
59. Ncgc00249613-13
60. Ac-27051
61. As-17059
62. Hy-10455
63. Smr004660024
64. Sw218090-2
65. D08880
66. Ab01565867_02
67. Sr-01000941582
68. J-501773
69. Sr-01000941582-1
70. Q15366934
71. (alphas)-alpha-((4-morpholinylacetyl)amino)benzenebutanoyl-l-leucyl-n-((1s)-3-methyl-1-(((2r)-2-methyloxiranyl)carbonyl)butyl)-l-phe Nylalaninamide
72. (s)-4-methyl-n-((s)-1-((s)-4-methyl-1-((r)-2- Methyloxiran-2-yl)-1 -oxopentan-2-ylamino)-1-oxo-3-phenylpropan-2-yl)-2-((s)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide
73. L-phenylalaninamide, (.alpha.s)-.alpha.-((4-morpholinylacetyl)amino)benzenebutanoyl-l-leucyl-n-((1s)-3-methyl-1-(((2r)-2-methyloxiranyl)carbonyl)butyl)-
74. L-phenylalaninamide, (alphas)-alpha-((4-morpholinylacetyl)amino)benzenebutanoyl-l-leucyl-n-((1s)-3-methyl-1-(((2r)-2-methyloxiranyl)carbonyl)butyl)-
Molecular Weight | 719.9 g/mol |
---|---|
Molecular Formula | C40H57N5O7 |
XLogP3 | 4.7 |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 20 |
Exact Mass | 719.42579917 g/mol |
Monoisotopic Mass | 719.42579917 g/mol |
Topological Polar Surface Area | 159 Ų |
Heavy Atom Count | 52 |
Formal Charge | 0 |
Complexity | 1180 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 5 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 2 | |
---|---|
Drug Name | Kyprolis |
PubMed Health | Carfilzomib (Injection) |
Drug Classes | Antineoplastic Agent |
Drug Label | KYPROLIS (carfilzomib) for Injection is an antineoplastic agent available for intravenous use only. KYPROLIS is a sterile, white to off-white lyophilized powder and is available as a single-use vial. Each vial of KYPROLIS contains 60mg of carfilzom... |
Active Ingredient | Carfilzomib |
Dosage Form | Powder |
Route | Intravenous |
Strength | 60mg/vial |
Market Status | Prescription |
Company | Onyx Pharms |
2 of 2 | |
---|---|
Drug Name | Kyprolis |
PubMed Health | Carfilzomib (Injection) |
Drug Classes | Antineoplastic Agent |
Drug Label | KYPROLIS (carfilzomib) for Injection is an antineoplastic agent available for intravenous use only. KYPROLIS is a sterile, white to off-white lyophilized powder and is available as a single-use vial. Each vial of KYPROLIS contains 60mg of carfilzom... |
Active Ingredient | Carfilzomib |
Dosage Form | Powder |
Route | Intravenous |
Strength | 60mg/vial |
Market Status | Prescription |
Company | Onyx Pharms |
Carfilzomib is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with lenalidomide and dexamethasone; or dexamethasone; or daratumumab and dexamethasone; or daratumumab and hyaluronidase-fihj and dexamethasone. It is also indicated as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.
FDA Label
Kyprolis in combination with daratumumab and dexamethasone, with lenalidomide and dexamethasone, or with dexamethasone alone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
Treatment of Multiple Myeloma
Treatment of acute lymphoblastic leukaemia
Intravenous carfilzomib administration resulted in suppression of proteasome chymotrypsin-like activity when measured in blood 1 hour after the first dose. On Day 1 of Cycle 1, proteasome inhibition in peripheral blood mononuclear cells (PBMCs) ranged from 79% to 89% at 15 mg/m2, and from 82% to 83% at 20 mg/m2. In addition, carfilzomib administration resulted in inhibition of the LMP2 and MECL1 subunits of the immunoproteasome ranging from 26% to 32% and 41% to 49%, respectively, at 20 mg/m2. Proteasome inhibition was maintained for 48 hours following the first dose of carfilzomib for each week of dosing. Resistance against carfilzomib has been observed and although the mechanism has not been confirmed, it is thought that up-regulation of P-glycoprotein may be a contributing factor. Furthermore, studies suggest that carfilzomib is more potent than bortezomib.
L01XX45
L01XX45
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
L - Antineoplastic and immunomodulating agents
L01 - Antineoplastic agents
L01X - Other antineoplastic agents
L01XG - Proteasome inhibitors
L01XG02 - Carfilzomib
Absorption
Cmax, single IV dose of 27 mg/m^2 = 4232 ng/mL; AUC, single IV dose of 27 mg/m^2 = 379 nghr/mL; Carfilzomib does not accumulation in the systemic. At doses between 20 and 36 mg/m2, there was a dose-dependent increase in exposure.
Volume of Distribution
Vd, steady state, 20 mg/m^2 = 28 L
Clearance
Systemic clearance = 151 - 263 L/hour. As this value exceeds hepatic blood flow, it suggests that carfilozmib is cleared extrahepatically.
Carfilzomib was rapidly and extensively metabolized by the liver. The predominant metabolites were the peptide fragments and the diol of carfilzomib which suggests that the main metabolic pathways are peptidase cleavage and epoxide hydrolysis. The cytochrome P450 enzyme system is minimally involved in the metabolism of carfilzomib. All metabolites are inactive.
Following intravenous administration of doses 15 mg/m^2, carfilzomib was rapidly cleared from the systemic circulation with a half-life of 1 hour on Day 1 of Cycle 1.
Carfilzomib is made up of four modified peptides and acts as a proteasome inhibitor. Carfilzomib irreversibly and selectively binds to N-terminal threonine-containing active sites of the 20S proteasome, the proteolytic core particle within the 26S proteasome. This 20S core has 3 catalytic active sites: the chymotrypsin, trypsin, and caspase-like sites. Inhibition of the chymotrypsin-like site by carfilzomib (5 and 5i subunits) is the most effective target in decreasing cellular proliferation, ultimately resulting in cell cycle arrest and apoptosis of cancerous cells. At higher doses, carfilzomib will inhibit the trypsin-and capase-like sites.
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Dosage Form : Capsule, Injectable / Parenteral, Nasal Solution, Ophthalmic Solution, Tablet, Topical Film
Grade : Parenteral, Oral, Ophthalmic...
Category : Dry Powder Inhalation, Emulsifying Agents, Parenteral, Solubilizers, Taste Masking, Thickeners and Stabilizers
Application : Dry Powder Inhalation, Emulsifying Agents, Parenteral, Solubilizers, Taste Masking, Thickeners and Stabilizers
Pharmacopoeia Ref : USP NF
Technical Specs : Captisol® is a polyanionic beta-cyclodextrin derivative with a s...
Ingredient(s) : Betadex Sulfobutyl Ether Sodium Excipient
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
A Carfilzomib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Carfilzomib, including repackagers and relabelers. The FDA regulates Carfilzomib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Carfilzomib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Carfilzomib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Carfilzomib supplier is an individual or a company that provides Carfilzomib active pharmaceutical ingredient (API) or Carfilzomib finished formulations upon request. The Carfilzomib suppliers may include Carfilzomib API manufacturers, exporters, distributors and traders.
click here to find a list of Carfilzomib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Carfilzomib DMF (Drug Master File) is a document detailing the whole manufacturing process of Carfilzomib active pharmaceutical ingredient (API) in detail. Different forms of Carfilzomib DMFs exist exist since differing nations have different regulations, such as Carfilzomib USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Carfilzomib DMF submitted to regulatory agencies in the US is known as a USDMF. Carfilzomib USDMF includes data on Carfilzomib's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Carfilzomib USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Carfilzomib suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Carfilzomib Drug Master File in Korea (Carfilzomib KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Carfilzomib. The MFDS reviews the Carfilzomib KDMF as part of the drug registration process and uses the information provided in the Carfilzomib KDMF to evaluate the safety and efficacy of the drug.
After submitting a Carfilzomib KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Carfilzomib API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Carfilzomib suppliers with KDMF on PharmaCompass.
A Carfilzomib written confirmation (Carfilzomib WC) is an official document issued by a regulatory agency to a Carfilzomib manufacturer, verifying that the manufacturing facility of a Carfilzomib active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Carfilzomib APIs or Carfilzomib finished pharmaceutical products to another nation, regulatory agencies frequently require a Carfilzomib WC (written confirmation) as part of the regulatory process.
click here to find a list of Carfilzomib suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Carfilzomib as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Carfilzomib API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Carfilzomib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Carfilzomib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Carfilzomib NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Carfilzomib suppliers with NDC on PharmaCompass.
Carfilzomib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Carfilzomib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Carfilzomib GMP manufacturer or Carfilzomib GMP API supplier for your needs.
A Carfilzomib CoA (Certificate of Analysis) is a formal document that attests to Carfilzomib's compliance with Carfilzomib specifications and serves as a tool for batch-level quality control.
Carfilzomib CoA mostly includes findings from lab analyses of a specific batch. For each Carfilzomib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Carfilzomib may be tested according to a variety of international standards, such as European Pharmacopoeia (Carfilzomib EP), Carfilzomib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Carfilzomib USP).
LOOKING FOR A SUPPLIER?